Learn everything you need to know about Deflazacort-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Review the side-effects of Deflazacort as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Patients with Duchenne muscular dystrophy (DMD) are prescribed corticosteroid anti-inflammatory drugs as standard of care, but long-term use comes with significant adverse effects. For individuals ...

NORTHBROOK, Ill.--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC (Marathon), a U.S. research-based biopharmaceutical company focused solely on the development of new treatments for rare diseases, ...

Both low and high doses of deflazacort (Marathon Pharmaceuticals) are effective in increasing muscle strength in children and adolescents with Duchenne muscular dystrophy (DMD), suggests results of a ...

An old steroid treatment, long available outside the United States, received approval this week for a rare disease that afflicts about 15,000 Americans. Though not previously approved in the United ...

A newly US-approved drug with an $89,000-a-year price tag has been put on hold, owing to the latest uproar from advocates and lawmakers over high drug prices. The drug, a steroid called deflazacort, ...

Daily corticosteroid use is significantly more effective than an intermittent regimen for improving motor function in patients with Duchenne muscular dystrophy (DMD), a new study suggests. DMD is a ...

Deflazacort helps treats patients with a rare disease called Duchenne muscular dystrophy The drug will now cost $35,000 a year for a patient in the U.S. weighing 25 kilograms, or about 55 pounds The ...

Zydus Lifesciences Limited on Monday said it received final approval from the health regulator of the United States for Deflazacort oral suspension used for treating a severe form of muscular ...

Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation 80% fewer patients with vertebral fractures (8 ...